CASI Pharmaceuticals, Inc. (CASI)
NASDAQ: CASI · Real-Time Price · USD
1.840
+0.050 (2.79%)
At close: Jun 13, 2025, 4:00 PM
1.850
+0.010 (0.54%)
After-hours: Jun 13, 2025, 7:45 PM EDT
CASI Pharmaceuticals Revenue
CASI Pharmaceuticals had revenue of $6.24M in the quarter ending March 31, 2025, with 83.04% growth. This brings the company's revenue in the last twelve months to $31.37M, up 8.39% year-over-year. In the year 2024, CASI Pharmaceuticals had annual revenue of $28.54M, down -15.77%.
Revenue (ttm)
$31.37M
Revenue Growth
+8.39%
P/S Ratio
0.93
Revenue / Employee
$134,627
Employees
233
Market Cap
28.51M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.54M | -5.34M | -15.77% |
Dec 31, 2023 | 33.88M | -9.23M | -21.41% |
Dec 31, 2022 | 43.11M | 12.94M | 42.89% |
Dec 31, 2021 | 30.17M | 15.03M | 99.25% |
Dec 31, 2020 | 15.14M | 11.01M | 266.52% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CASI News
- 27 days ago - CASI Pharmaceuticals Provides Business and Clinical Update - Accesswire
- 4 weeks ago - CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results - Accesswire
- 4 weeks ago - CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China - Accesswire
- 5 weeks ago - CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement - Accesswire
- 2 months ago - CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company - Accesswire
- 2 months ago - CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results - Accesswire
- 5 months ago - CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia - Accesswire
- 7 months ago - CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results - Accesswire